DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Doi.org Make Money
Keywords
Topics
Schema
External Links
Analytics And Tracking
Libraries
Hosting Providers

We began analyzing https://link.springer.com/protocol/10.1007/978-1-4939-8958-4_4, but it redirected us to https://link.springer.com/protocol/10.1007/978-1-4939-8958-4_4. The analysis below is for the second page.

Title[redir]:
Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies | SpringerLink
Description:
Metastatic melanoma is a dreadful type of skin cancer arising due to uncontrolled proliferation of melanocytes. It has very poor prognosis, low 5-year survival rates and until recently there were only handful of treatment options for metastatic melanoma patients. The...

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don't see any clear sign of profit-making.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Doi.org might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

pubmed, google, scholar, article, cas, immunol, cancer, central, cell, melanoma, antibodies, cells, activation, ctla, human, immunotherapy, rotte, monoclonal, immune, tigit, springer, nat, immunity, treatment, bhandaru, gene, biol, tim, rev, regulates, nivolumab, lag, wang, tolerance, death, receptor, protocol, response, antibody, receptors, res, tcell, nature, protein, responses, book, molecular, rates, inhibitory, ipilimumab,

Topics {✒️}

tumor-infiltrating ny-eso-1-specific cd8+ gov/newsevents/newsroom/pressannouncements/ucm560167 gov/drugs/informationondrugs/approveddrugs/ucm569366 cd11b+ly-6g+ myeloid cells anti-pd-l1 antibodies atezolizumab antibody-dependent cellular cytotoxicity month download article/chapter anti-pd-1 antibody nivolumab unexpected n-terminal loop sustains t-cell anergy influences t-cell activation cell-intrinsic inhibitory functions anti-ctla-4 antibody ipilimumab pd-1 receptor-deficient mice itim motif-carrying immunoreceptor peripheral t-cell tolerance anti-programmed death-1 small-cell lung cancer natural killer cells tim-3/galectin-9 inhibitory interaction cd3/tcr complex human monoclonal antibodies pd-1/pd-l1 blockade south san francisco fc-receptor interactions regulate interleukin-2 receptor signaling specific genetic feature nf-kappab activity anti-pd-1 antibodies pd-l1 regulates tim-3 ligand regulates human pd-1 gene programmed cell death lymphocyte activation gene-3 lymphocyte-activation gene-3 privacy choices/manage cookies program death-1 engagement neutralizing antibody activities wherry ej tan dj device instant download nk cell recognition receptor/poliovirus receptor human fcgamma receptors human igg subclasses t-cell immunoglobulin tim-3/galectin-9 pathway advanced squamous-cell costimulation-dependent activation human colorectal carcinoma

Schema {🗺️}

ScholarlyArticle:
      headline:Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies
      pageEnd:108
      pageStart:83
      image:https://media.springernature.com/w153/springer-static/cover/book/978-1-4939-8958-4.jpg
      genre:
         Springer Protocols
      isPartOf:
         name:Human Monoclonal Antibodies
         isbn:
            978-1-4939-8958-4
            978-1-4939-8957-7
         type:Book
      publisher:
         name:Springer New York
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Madhuri Bhandaru
            affiliation:
                  name:University of British Columbia
                  address:
                     name:Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anand Rotte
            affiliation:
                  name:Genentech Research and Early Development
                  address:
                     name:Department of Clinical Pharmacology, Genentech Research and Early Development, South San Francisco, USA
                     type:PostalAddress
                  type:Organization
                  name:Nevro Corp.
                  address:
                     name:Department of Clinical and Regulatory Affairs, Nevro Corp., Redwood City, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      keywords:Co-stimulation, Checkpoints, T cells, CTLA-4, PD-1, TIGIT, TIM-3, LAG-3, ADCC
      description:Metastatic melanoma is a dreadful type of skin cancer arising due to uncontrolled proliferation of melanocytes. It has very poor prognosis, low 5-year survival rates and until recently there were only handful of treatment options for metastatic melanoma patients. The drugs that were approved for the treatment had low response rates and were associated with severe adverse events. With the introduction of monoclonal antibodies against inhibitory immune checkpoints the treatment landscape for metastatic melanoma has changed dramatically. Ipilimumab, the first monoclonal antibody to be approved for the treatment of metastatic melanoma, showed significant improvements in durable response rates in patients and paved the way for next class of monoclonal antibodies. Nivolumab and pembrolizumab, the anti-PD-1 antibodies that were approved 3-years after the approval of ipilimumab, had decent response rates, low relapse rates and showed manageable safety profile. Antibodies against ligands for PD-1 receptors were then developed to overcome the adverse effects of anti-PD-1 antibodies and combination of monoclonal antibodies (ipilimumab plus nivolumab) was tested to increase the response rates. Additional target receptors that regulate T cell activity were identified on T cells and monoclonal antibodies against potential targets such as TIGIT, TIM-3, and LAG-3 were developed. This chapter discusses the details of monoclonal antibodies used for the treatment of melanoma along with the ones that could be introduced in the near future with emphasis on mechanisms by which antibodies stimulate anti-tumor immune response and the specifics of target molecules of the antibodies.
      datePublished:2019
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
      context:https://schema.org
Book:
      name:Human Monoclonal Antibodies
      isbn:
         978-1-4939-8958-4
         978-1-4939-8957-7
Organization:
      name:Springer New York
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of British Columbia
      address:
         name:Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada
         type:PostalAddress
      name:Genentech Research and Early Development
      address:
         name:Department of Clinical Pharmacology, Genentech Research and Early Development, South San Francisco, USA
         type:PostalAddress
      name:Nevro Corp.
      address:
         name:Department of Clinical and Regulatory Affairs, Nevro Corp., Redwood City, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Madhuri Bhandaru
      affiliation:
            name:University of British Columbia
            address:
               name:Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:Anand Rotte
      affiliation:
            name:Genentech Research and Early Development
            address:
               name:Department of Clinical Pharmacology, Genentech Research and Early Development, South San Francisco, USA
               type:PostalAddress
            type:Organization
            name:Nevro Corp.
            address:
               name:Department of Clinical and Regulatory Affairs, Nevro Corp., Redwood City, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada
      name:Department of Clinical Pharmacology, Genentech Research and Early Development, South San Francisco, USA
      name:Department of Clinical and Regulatory Affairs, Nevro Corp., Redwood City, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(399)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js

Emails and Hosting {✉️}

Mail Servers:

mx.zoho.eu
mx2.zoho.eu
mx3.zoho.eu

Name Servers:

josh.ns.cloudflare.com
zita.ns.cloudflare.com

6.4s.